The drug known as JZP-110 significantly improved wakefulness and reduced sleepiness in patients whose breathing interrupts their sleep, Jazz said in a new release. Jazz enrolled 476 patients and tested four doses of JZP-110 plus a placebo.
All four doses showed a statistically significant improvement vs. the placebo over the course of the 12-week trial, Jazz said. The company will present full results during the Associated Professional Sleep Societies annual meeting in June in Boston.
In a second six-week study, 126 patients reported "much" or "very much" improvement at week four on the Patient Global Impression of Change scale, which scores a patient's belief about the efficacy of treatment.
JZP-110 is also being studied in narcolepsy and has "orphan drug" status. Orphan drugs treat rare diseases. Companies are incentivized with tax credits to develop orphan drugs because they otherwise likely won't recoup the costs of development.
No comments:
Post a Comment